Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investmen... (nerate novel lead molecules for key ther...)

HOME >> BIOLOGY >> TECHNOLOGY

Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners

Date:11/27/2007

nerate novel lead molecules for key therapeutic targets." commented Cherrell Hirst, QBF CEO and Innovis General Partner.

Xenome information:

Lewis Lee

Director & CEO

Xenome Ltd

Tel: +61 7 3720 8055

E-mail: lewis.lee@xenome.com

Website: http://www.xenome.com

QBF and Innovis Information:

Cherrell Hirst MD (CEO)

QBF Pty Ltd.

Tel: +61 7 3009 6850

E-mail: c.hirst@qbf.qic.com

Website: http://www.qic.com

About Xenome

Xenome is a progressive Australian biotechnology company with a promising and distinctive technology platform targeting pain and inflammation. Xen2174, the Company's lead drug candidate is currently completing a Phase 1b/2a clinical trial for cancer pain with evidence to date providing strong support that the trial endpoints will be successfully met. More substantive clinical trials for expanded indications are planned for 2008. In addition, the drug discovery platform from which Xen2174 emerged has inherent value due to its ability to repeatedly identify new lead medicinal compounds on the basis of its unique construction around Australian biodiversity. Specifically, Xenome has generated a unique expertise in peptide chemistry to translate the evolutionary advantages inherent in venom peptides into highly bioactive libraries of molecules that are of interest to global biotechnology and pharmaceutical companies.

http://www.xenome.com

About QBF

Queensland BioCapital Funds Pty Ltd (QBF) is a $100 million closed end venture capital fund that seeks to invest in listed or unlisted companies in the human biosciences sector, in particular, pharmaceuticals, medical devices, consumer healthcare products and diagnostics. It i
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance

Post Your Comments:

Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investmen...(nerate novel lead molecules for key ther...)